MDGL
Madrigal Pharmaceuticals, Inc. Health Care Pharmaceutical Preparations Russell 3000
$430.36Close
$9.8BMarket cap
$412.35 – $602.8352-week range
Nov 3, 2026Next report · before the open
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 27 · weaker than 73% of stocks over 12 months
- Far from its high 29% below its 52-week high
- Distribution down-day volume 1.7× up-day volume over 50 sessions
- Results soon Nov 3, 2026, in 2 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
29%
1wk
down 0.9%
price change
1mo
down 14.6%
price change
12-month return
up 1%
market up 11% ·
its own down 9%
F-score
—
— Not assessed
Altman Z
7.52
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
16.3×
price / book
Earnings yield
down 3.0%
EBIT / enterprise value
Cheaper than
14%
of the market · expensive
Revenue growth
up 432%
year on year
EPS growth
—
latest quarter
Sales growth
up 71%
latest quarter · -56 pts
ROE
down 42%
return on equity
Free cash margin
down 20%
-$190.0M FCF
D/E
0.56
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
3.8%
$16.34 a day · 2×ATR $397.68
RS
27 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
0.58
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 3.8% over the year, from 22m to 23m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Jul 30, 2026
Last shock
Jul 30, 2026-10% in one session3.9× volumeon results-13% since
Financials
- Net -30%
- Free cash -20%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $180.1M | $958.4M |
| Gross margin | — | — | — | — | 97% | — |
| Operating income | -$206.7M | -$242.5M | -$293.6M | -$380.5M | -$497.9M | -$300.1M |
| Net income | -$202.2M | -$241.8M | -$295.2M | -$373.6M | -$465.9M | -$288.3M |
| Net margin | — | — | — | — | -259% | -30% |
| Earnings per share | -$13.09 | -$14.63 | -$17.23 | -$17.33 | -$17.31 | -$10.15 |
| Free cash flow | -$157.9M | -$184.1M | -$225.1M | -$325.7M | -$457.0M | -$190.0M |
| Free cash margin | — | — | — | — | -254% | -20% |
| Cash | $54.0M | $36.3M | $331.5M | $99.9M | $100.0M | $198.7M |
| Long-term debt | — | $0 | $49.3M | $115.5M | $117.6M | $339.9M |
| Shareholders' equity | $240.0M | $196.1M | $197.4M | $405.3M | $754.4M | $602.7M |
| Shares outstanding | 15.51m | 17.10m | 18.10m | 19.88m | 22m | 22.84m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 19, 2026 | Annual ↗ | Dec 31, 2025 | 50d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 1, 2025 | Quarterly ↗ | Mar 31, 2025 | 31d |
| Feb 26, 2025 | Annual ↗ | Dec 31, 2024 | 57d |
| Oct 31, 2024 | Quarterly ↗ | Sep 30, 2024 | 31d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 12, 2026 | Director or officer change · Regulation FD ↗ |
| Jul 30, 2026 | Results ↗ |
| Jun 17, 2026 | Director or officer change · Shareholder vote ↗ |
| May 6, 2026 | Results ↗ |
| Apr 28, 2026 | Director or officer change ↗ |
| Feb 19, 2026 | Results ↗ |
| Jan 30, 2026 | Material agreement ↗ |
| Dec 11, 2025 | Director or officer change ↗ |
| Nov 4, 2025 | Results ↗ |
| Aug 5, 2025 | Results ↗ |
| Jul 30, 2025 | Regulation FD ↗ |
| Jul 22, 2025 | Material agreement · Agreement ended · New obligation · Regulation FD ↗ |